Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16209368 | 0.75 | ATM (0.39) | KDM4ELMNA | |
| SCHEMBL16209367 | 0.75 | ATM (0.39) | KDM4ELMNA | |
| SCHEMBL16209370 | 0.75 | ATM (0.39) | KDM4ELMNA | |
| SCHEMBL6204247 | 0.75 | KDM4E (0.43) | KDM4ECYP3A4CA1CA2CA7 | |
| SCHEMBL28436076 | 0.75 | KDM4E (0.43) | KDM4ECYP3A4CA1CA2CA7 | |
| SCHEMBL14966073 | 0.71 | KDM4E (0.47) | KDM4ESLC2A1LMNA | |
| SCHEMBL15920753 | 0.71 | KDM4E (0.40) | KDM4ECYP3A4CA1CA2CA7 | |
| SCHEMBL16209582 | 0.71 | KDM4E (0.47) | KDM4ESLC2A1LMNA | |
| SCHEMBL11236067 | 0.71 | KDM4E (0.54) | KDM4ECYP3A4LMNA | |
| SCHEMBL28438637 | 0.70 | KDM4E (0.43) | KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224208-A1 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2011-09-15 | — | — | US | disclosed |
| US-20110224208-A1 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2011-09-15 | — | — | US | disclosed |
| US-20110224208-A1 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2011-09-15 | — | — | US | disclosed |
| EP-2358682-A2 | ISOQUINOLONE DERIVATIVES AS INHIBITORS OF PLAVIVIRUS REPLICATION | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010055164-A2 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010055164-A2 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2010-05-20 | — | — | WO | disclosed |
| EP-0061881-A1 | Ruminant feed method for improving the efficiency of ruminant feed utilization | ELI LILLY AND COMPANY (US) | 1982-10-06 | — | — | EP | disclosed |
| US-4333923-A | 3-(TRICHLOROMETHYL)PHTHALIDES | ELI LILLY AND COMPANY (US) | 1982-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224208-A1 | NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION | MAVS, IRF3, EIF2AK2 | KDM4E 2120/4885CYP3A4 722/4885SLC2A1 4562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.